Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

LSL60101 compound may produce efficaciousness for Alzheimer’s disease and neuroinflammation

Staff Writer
Staff Writer 2 years ago
Updated 2021/06/30 at 12:12 AM
Share
SHARE

Following the controversial approval of the amyloid-beta antagonist treatment aducanumab, Spanish researchers at the University of Barcelona have been testing the LSL60101 compound, with the potential to treat Alzheimer’s disease and neuroinflammation.

According to their study, released in the European Journal of Medicinal Chemistry and the British Journal of Pharmacology, the testing of rodents yielded improvements in cognitive deficits and may prove to be beneficial for treating certain neurogenerative diseases.

“Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases,” the study reads.

“In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable.”

Researchers uncovered a neuroprotective role when testing LSL60101, known as garsevil, through its reduction of apoptosis and modulation of oxidative stress.

Its use may be significant for combatting the formation of amyloid-beta plaques in the brain, potentially becoming a neuroinflammatory treatment for diseases like Alzheimer’s disease.

LSL60101 was even compared with donepezil, a commonly used drug treatment for cognitive deficits, with the combination of both demonstrating efficaciousness for the neurodegenerative disease.

“Everything points out to the fact that the interaction of this drug with its receptor is involved in the generation of proinflammatory molecules that would increase the ongoing neuroinflammation in the disease. Therefore, I2 ligands would contribute to reduce the inflammation and thus, would slow the progression of the disease,” researchers stated in their study.

You Might Also Like

Cognitive disorders may develop due to molecular overreaction to ribosome stalling

Researchers have uncovered hints as to why immune cells appear to cause brain damage

Researchers use AI to generate video from brain activity

People are more creative upon awakening from the earliest stage of sleep: new study

Memory loss associated with Alzheimer’s may be mitigated through deep sleep

TAGGED: amyloid pathology, LSL60101, Alzheimer's disease, cognition, neuroinflammation
Staff Writer June 29, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article More screen time in children linked to higher rates of child obesity
Next Article E-cigarettes could be more beneficial than nicotine replacement treatment for smokers

Recommended

Clinical

Cognitive disorders may develop due to molecular overreaction to ribosome stalling

2 Min Read
Clinical

Researchers have uncovered hints as to why immune cells appear to cause brain damage

1 Min Read
Clinical

Researchers use AI to generate video from brain activity

2 Min Read
Clinical

People are more creative upon awakening from the earliest stage of sleep: new study

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?